Schneider M - Search Results

1

The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease.

Schnur S, Hans F, Dehne A, Osti J, Schneemann MO, Schneider M, Hittinger M. Schnur S, et al. Among authors: schneider m. Pharmaceuticals (Basel). 2023 May 14;16(5):748. doi: 10.3390/ph16050748. Pharmaceuticals (Basel). 2023. PMID: 37242530 Free PMC article.

2

Macrophage uptake of cylindrical microparticles investigated with correlative microscopy.

Tscheka C, Hittinger M, Lehr CM, Schneider-Daum N, Schneider M. Tscheka C, et al. Among authors: schneider m, schneider daum n. Eur J Pharm Biopharm. 2015 Sep;95(Pt A):151-5. doi: 10.1016/j.ejpb.2015.03.010. Epub 2015 Mar 14. Eur J Pharm Biopharm. 2015. PMID: 25779350

3

Preparation of maltodextrin nanoparticles and encapsulation of bovine serum albumin - Influence of formulation parameters.

Barthold S, Hittinger M, Primavessy D, Zapp A, Groß H, Schneider M. Barthold S, et al. Among authors: schneider m. Eur J Pharm Biopharm. 2019 Sep;142:405-410. doi: 10.1016/j.ejpb.2019.07.003. Epub 2019 Jul 6. Eur J Pharm Biopharm. 2019. PMID: 31288078

4

Pulmonary in vitro instruments for the replacement of animal experiments.

Primavessy D, Metz J, Schnur S, Schneider M, Lehr CM, Hittinger M. Primavessy D, et al. Among authors: schneider m. Eur J Pharm Biopharm. 2021 Nov;168:62-75. doi: 10.1016/j.ejpb.2021.08.005. Epub 2021 Aug 24. Eur J Pharm Biopharm. 2021. PMID: 34438019 Review.

5

Inflammatory bowel disease addressed by Caco-2 and monocyte-derived macrophages: an opportunity for an in vitro drug screening assay.

Schnur S, Wahl V, Metz JK, Gillmann J, Hans F, Rotermund K, Zäh RK, Brück DA, Schneider M, Hittinger M. Schnur S, et al. Among authors: schneider m. In Vitro Model. 2022;1(4-5):365-383. doi: 10.1007/s44164-022-00035-8. Epub 2022 Nov 3. In Vitro Model. 2022. PMID: 37520160 Free PMC article.

6

Human Skin Permeation Enhancement Using PLGA Nanoparticles Is Mediated by Local pH Changes.

Luengo J, Schneider M, Schneider AM, Lehr CM, Schaefer UF. Luengo J, et al. Among authors: schneider m, schneider am. Pharmaceutics. 2021 Oct 3;13(10):1608. doi: 10.3390/pharmaceutics13101608. Pharmaceutics. 2021. PMID: 34683901 Free PMC article.

7

In Vitro, Ex Vivo, and In Vivo Evaluation of Nanoparticle-Based Topical Formulation Against Candida albicans Infection.

Sadozai SK, Khan SA, Baseer A, Ullah R, Zeb A, Schneider M. Sadozai SK, et al. Among authors: schneider m. Front Pharmacol. 2022 Jul 8;13:909851. doi: 10.3389/fphar.2022.909851. eCollection 2022. Front Pharmacol. 2022. PMID: 35873577 Free PMC article.

8

Impact of mucus modulation by N-acetylcysteine on nanoparticle toxicity.

Meziu E, Shehu K, Koch M, Schneider M, Kraegeloh A. Meziu E, et al. Among authors: schneider m. Int J Pharm X. 2023 Sep 21;6:100212. doi: 10.1016/j.ijpx.2023.100212. eCollection 2023 Dec 15. Int J Pharm X. 2023. PMID: 37771516 Free PMC article.

9

Cylindrical Microparticles Composed of Mesoporous Silica Nanoparticles for the Targeted Delivery of a Small Molecule and a Macromolecular Drug to the Lungs: Exemplified with Curcumin and siRNA.

Fischer T, Winter I, Drumm R, Schneider M. Fischer T, et al. Among authors: schneider m. Pharmaceutics. 2021 Jun 7;13(6):844. doi: 10.3390/pharmaceutics13060844. Pharmaceutics. 2021. PMID: 34200405 Free PMC article.

10

Inhalative nanomedicine--opportunities and challenges.

Bur M, Henning A, Hein S, Schneider M, Lehr CM. Bur M, et al. Among authors: schneider m. Inhal Toxicol. 2009 Jul;21 Suppl 1:137-43. doi: 10.1080/08958370902962283. Inhal Toxicol. 2009. PMID: 19558246 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,262 results

Search Page